LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About 4D pharma Stock (LON:DDDD) Get 4D pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read More Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DDDD Stock News HeadlinesYieldMax® ETFs Announces First Quarterly Distribution for the U.S. Stocks Target Double Distribution ETF (DDDD)July 1, 2026 | globenewswire.comYou Already Own SCHD. This New ETF Pays Twice the Yield With One Simple SwapMarch 19, 2026 | 247wallst.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 13 at 1:00 AM | Chaikin Analytics (Ad)4D Molecular Therapeutics expands phase 3 trial enrollmentDecember 10, 2025 | msn.com4D Molecular Therapeutics Appoints New Chief Financial OfficerNovember 17, 2025 | msn.com4D Molecular Therapeutics Names Kristian Humer Chief Financial OfficerNovember 17, 2025 | marketwatch.comChardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy RecommendationNovember 12, 2025 | msn.com4D Molecular Therapeutics Reports Positive Interim Trial ResultsNovember 6, 2025 | msn.comSee More Headlines DDDD Stock Analysis - Frequently Asked Questions How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) issued its quarterly earnings data on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter. How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Omega Diagnostics Group (ODX), Tullow Oil (TLW), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings9/30/2020Today8/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:DDDD CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£31.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.44 Book ValueGBX 18 per share Price / BookN/AMiscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.05 million OptionableNot Optionable Beta2.63 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (LON:DDDD) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
